310 results on atopic dermatitis
In this study we want to evaluate the safety and efficacy of the new drug ZPL389. ZPL389 is tested in various strengths in patients with moderate or severe atopic dermatitis. The effects of ZPL389 are compared with those of a placebo.
The primary objective of this study is to compare the therapeutic effect on atopic dermatitis of a skin barrier repair cream (Dermalex eczema) in contrast to a standard used emollient (unguentum leniens FNA) and a dermatocorticoid (hydrocortisone)…
EFFICACY OBJECTIVESThe primary efficacy objective for this study is to evaluate the efficacy of lebrikizumabused as adjunctive therapy with TCS compared with TCS in patients with persistentmoderate to severe AD, as measured by Eczema Area and…
2.1 Primary study objectiveThe primary objective of this study is to investigate the therapeutic effect of an extensively hydrolyzed protein based infant formula with a synbiotic mixture on the severity of atopic dermatitis in infants.2.2 Secondary…
To objectify skin barrier repair characteristics of coal tar in atopic dermatitis patients, by quantifying changes in NMF, lipid levels, TEWL, SCORAD-score and cytokine levels
Primary Objective: To investigate longitudinal variation of blood-based biomarkers, their integration with disease severity, comorbidities, their association with standard care and characterization of adequate and inadequate responders to standard…
To compare the clinical outcome of daily showering followed by immediate application of emollient to once weekly showering followed by immediate application of emollient, in children with mild to moderate AD. The primary outcome parameter will be…
To investigate whether atopic dermatitis patients can be stratified based on integral analysis of clinical patient data complemented by novel biophysical measurements, in-vivo Raman spectroscopy, microbiome swabs and a oral mucosa swab (one time).
A positive effect of using test product with respect to the change of SCORAD after 4 months of intervention in subjects with atopic dermatitis.
To evaluate the additional effect of coal tar treatment to a corticosteroid regimen in adults (aged >16 years of age) with moderate to severe atopic dermatitis, based on the percentage change in Eczema Area and Severity Index (EASI) at week 2…
The use of the oral immunosuppressant Myfortic® in the treatment of atopic dermatitis might be responsible for the delay the repair of DNA-damage in the skin after UV-exposition.
To evaluate the safety and efficacy of multiple doses of ABT-494 (Upadacitinib) monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis.
Primary objective:To demonstrate the efficacy of dupilumab administered concomitantly with TCS through week 16 in adult patients with moderate-to-severe atopic dermatitis (AD).Secondary objectives:Evaluate long-term efficacy of dupilumab when…
The objective of the study is to assess the long-term safety of tacrolimus ointment 0.03% or 0.1% in the treatment of subjects with atopic dermatitis under actual use conditions, including the risk of developing cutaneous or systemic malignancies.…
Primary: To demonstrate the efficacy of QGE031 relative to placebo at 12 weeks in patients withatopic dermatitis (AD) as assessed by Eczema Area and Severity Index (EASI).Secondary: efficacy assessed by Investigator Global Assessment (IGA, 12 weeks…
Primary objective: The primary objective is to assess the efficacy and safety of nemolizumab (CD14152) after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
Primary study objectiveTo investigate the prevalence of asthma in children up to 7 years of age with atopic dermatitis in infancy who received either Nutrilon Pepti with synbiotics or Nutrilon Pepti without synbiotics during 12 weeks in their first…
We hypothesize that e-health, consisting of internet guided monitoring and self management training online, for patients with atopic dermatitis combines cost savings with an improvement in quality of life.
To determine the frequency and suppressive potential of skin resident regulatory T cells isolated from atopic dermatitis and psoriasis patients compared to healthy control subjects (the latter data will be obtained by co-workers at the Brigham and…
To determine the functional capacities of regulatory T cells present in lesional and non-lesional atopic dermatitis skin, and lesional and non-lesional psoriasis vulgaris skin.